YHLO Helps China’s Top Ranking Hospital PUMCH to Upgrade from Traditional ELISA to CLIA Technology
By LabMedica International staff writers Posted on 06 Jan 2021 |
Image: iModules Integration System for Immunoassay (Photo courtesy of Shenzhen YHLO Biotech Co., Ltd.)
Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) has helped China’s top ranking hospital, Peking Union Medical College Hospital (PUMCH; Beijing, China), to successfully upgrade its laboratory from the traditional ELISA (enzyme-linked immunoassay) technology to CLIA (chemiluminescence immunoassay) technology.
PUMCH, founded by the Rockefeller Foundation in 1921, has been designated by China’s Ministry of Health as one of the most authoritative centers for diagnosis and treatment of complex diseases. PUMCH’s department of Rheumatology and Immunology is the earliest dedicated department for rheumatology and immunology in China. The department’s laboratory is capable of diagnosing nearly 100 kinds of auto-antibodies, making it one of the largest auto-antibody diagnosing centers in China. In August 2020, the department upgraded its laboratory from the traditional ELISA technology to CLIA technology with the cooperation of YHLO.
With the help of YHLO’s iModules Integration System for Immunoassay, PUMCH has become the first among the top Chinese hospitals to establish a fully automated assembly line. YHLO’s iModules series features a modular design that offers flexibility for expansion. With its high throughput, fast speed and multiple parameters, the series helps to process a higher number of samples in the laboratory, improve diagnostic results and shorten turnaround time. The parameters on the iModules platform include dsDNA IgG, SSA IgG, SSB IgG, RNP70 IgG, Sm IgG, Jo-1 IgG, Scl-70 IgG, anti-CCP, MPO IgG, PR3 IgG, Cardiolipin IgG/IgA/IgM/total and β2 Glycoprotein IgG/IgA/IgM/total, etc., providing more accurate and reliable quantitative results.
Related Links:
Shenzhen YHLO Biotech Co., Ltd.
Peking Union Medical College Hospital
PUMCH, founded by the Rockefeller Foundation in 1921, has been designated by China’s Ministry of Health as one of the most authoritative centers for diagnosis and treatment of complex diseases. PUMCH’s department of Rheumatology and Immunology is the earliest dedicated department for rheumatology and immunology in China. The department’s laboratory is capable of diagnosing nearly 100 kinds of auto-antibodies, making it one of the largest auto-antibody diagnosing centers in China. In August 2020, the department upgraded its laboratory from the traditional ELISA technology to CLIA technology with the cooperation of YHLO.
With the help of YHLO’s iModules Integration System for Immunoassay, PUMCH has become the first among the top Chinese hospitals to establish a fully automated assembly line. YHLO’s iModules series features a modular design that offers flexibility for expansion. With its high throughput, fast speed and multiple parameters, the series helps to process a higher number of samples in the laboratory, improve diagnostic results and shorten turnaround time. The parameters on the iModules platform include dsDNA IgG, SSA IgG, SSB IgG, RNP70 IgG, Sm IgG, Jo-1 IgG, Scl-70 IgG, anti-CCP, MPO IgG, PR3 IgG, Cardiolipin IgG/IgA/IgM/total and β2 Glycoprotein IgG/IgA/IgM/total, etc., providing more accurate and reliable quantitative results.
Related Links:
Shenzhen YHLO Biotech Co., Ltd.
Peking Union Medical College Hospital
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance